1.
Clin Infect Dis
; 71(2): 415-418, 2020 07 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31676905
RESUMO
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.